#United States #San Diego #Head and Neck Cancer #Inhibrx #INBRX-106

Inhibrx's Breakthrough in Cancer Treatment with INBRX-106

Inhibrx Biosciences, a clinical-stage biopharmaceutical company, has made headlines with the promising results from their Phase 2 clinical trial of INBRX-106. This treatment, a hexavalent OX40 agonist, has been tested in combination with pembrolizumab for patients suffering from treatment-naïve, metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). The results reveal a significant leap in the response rates compared to using pembrolizumab alone.

Key Findings of the Study

On September 8, 2026, Inhibrx shared the interim results of the HexAgon study, which showcased the strong efficacy of INBRX-106. The combination therapy demonstrated a confirmed objective response rate (cORR) of 48.3%, more than doubling the 26.5% rate seen with pembrolizumab monotherapy. Notably, 13.8% of patients in the combination group achieved a complete response (CR), while none in the control arm experienced such results. This robust response is especially pronounced among patients with HPV-positive tumors, where 80.0% reached a cORR, reflecting a substantial improvement over the 33.3% achieved by those receiving only pembrolizumab.

Furthermore, the treatment's progression-free survival (PFS) metrics are equally promising, with a median PFS of 9.6 months for patients receiving INBRX-106 plus pembrolizumab, compared to just 4.9 months for the control group. Follow-up data showed that roughly 72.4% of those on the combination remained progression-free after six months, vastly outperforming the 42.8% of pembrolizumab patients who achieved the same.

Safety Profile

The combination of INBRX-106 and pembrolizumab was generally well-tolerated, with side effects primarily being low-grade issues such as rash, fatigue, and diarrhea. Feedback from the treatment highlights not only the efficacy but also the manageable side effects that accompany this promising therapeutic strategy.

Mark Lappe, CEO of Inhibrx, expressed enthusiasm regarding the depth and durability of these responses, particularly in HPV-positive patients. He emphasized the potential of OX40-mediated T-cell costimulation and indicated plans for expansion into other tumor types and combinations with cancer vaccines. This strategy could pave the way for accelerated approval pathways, further emphasizing the significance of these results.

Future Directions

Inhibrx is set to expand the Phase 2 study, enrolling around 50 additional HPV-positive oropharyngeal squamous cell carcinoma patients. This will not only bolster the efficacy data but also aim for an accelerated regulatory pathway for INBRX-106. The company plans to collaborate with the FDA to initiate the Phase 3 portion of the HexAgon trial, presenting an opportunity to confirm the effectiveness of their innovative treatment strategy.

In addition to HNSCC, Inhibrx is exploring IND applications for INBRX-106 in other malignancies, including a Phase 1/2 trial focusing on non-small cell lung cancer (NSCLC) that is expected to yield initial results by mid-2027. The company is particularly interested in leveraging INBRX-106's ability to amplify T-cell responses, thus opening avenues for combination therapies with cancer vaccines, enhancing treatment efficacy across different cancers.

Conclusion

Inhibrx's latest results from the HexAgon study underline the transformative potential of INBRX-106 in targeting advanced head and neck cancer, especially for HPV-positive patients. As they move towards further trials and strategic expansions, this biopharmaceutical company is poised at the forefront of innovative cancer treatments, with significant implications for improving patient outcomes in complex malignancies. The upcoming webcast presentation will provide more details, reinforcing the hope surrounding INBRX-106's clinical capabilities and its role in the future of cancer therapy.